ArticleScientific reports2022
CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.Exploration of targeted anti-tumor therapy · 2025Pooled it
- Extracellular Vesicle Protein Panel Enables Early Lung Cancer Detection in a Large Clinical Cohort.Journal of extracellular vesicles · 2025Trial
- Preoperative CA125 and metabolic factors associated with high-risk pathology in endometrial cancer.Oncology letters · 2026Article
- A nomogram for predicting high-risk endometrial cancer based on the transvaginal ultrasonography and contrast-enhanced ultrasonography.Quantitative imaging in medicine and surgery · 2026Article
- A machine learning-based risk prediction framework for atypical hyperplasia and endometrial cancer in postmenopausal women.World journal of surgical oncology · 2026Article
- SERS-Based Immunoassay on Ag/ZnO Nanorod Substrates for Detection of CA125 Antigen.ACS measurement science au · 2026Article
- A Risk Prediction Model for Progression-Free Survival in Endometrial Cancer Integrating Clinicopathological Variables and Routine Laboratory Indicators.International journal of women's health · 2026Article
- A preoperative nomogram integrating transvaginal ultrasound endometrial thickness and nutritional, inflammatory, and metabolic indicators for predicting lymph node metastasis in endometrial cancer.Frontiers in public health · 2026Article
- TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.Cancer immunology research · 2025Review
- Characteristics of endometrial cancer progressed to extrauterine lesions following fertility preserving medroxyprogesterone acetate therapy for young endometrial cancer patients.Journal of gynecologic oncology · 2025Article
- Serum Levels of CA125 and HE4 as a Tool for Predicting Regional Lymph Node Metastatic Involvement in Endometrial Carcinoma.Cancers · 2025Article
- Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- A Nomogram for Preoperative Prediction of Tumor Aggressiveness and Lymphovascular Space Involvement in Patients with Endometrial Cancer.Journal of clinical medicine · 2025Article
- Exploring T-cell bispecific antibodies in gynecologic malignancy.Gynecologic oncology reports · 2025Review
- Predictive value of models based on MRI radiomics and clinical indicators for lymphovascular space invasion in endometrial cancer.BMC cancer · 2025Article
- Knockdown of HSF1 inhibits invasion, metastasis, and proliferation of endometrial carcinoma cells while promoting apoptosis.Cancer biomarkers : section A of Disease markers · 2025Article
- Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation.ACS omega · 2025Article
- Diagnostic Value of MRI for Pelvic Lymph Node Extracapsular Invasion in Early-Stage Endometrial Carcinoma.International journal of women's health · 2025Article
- Serum biomarkers and clinicopathologic postoperative prognostic factors for in endometrial cancer patients.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the most common malignancy of the female reproductive system. Cancer antigen 125 (CA125) is a serum tumor marker widely reported in EC patients, particularly those with poor prognostic factors such as grade 3 tumors, deep myometrial invasion, lymph node metastasis (LNM), and extra-uterine disease. This retrospective study stratifies pre-operative CA125 levels to evaluate odds ratios (OR) and relative risk (RR) between CA125 levels and the likelihood of +LNM, lymphovascular space invasion (LVSI), grade, and stage. Patient charts for women 18 years or older with a diagnosis of EC and pre-operative or within one week CA125 measurement from January 2000 to January 2015 at a regional hospital were reviewed. OR and RR were determined by unconditional maximum likelihood estimation for CA125 levels as the predictor with staging, grade, +LVSI and +LNM as outcomes. The largest increase in risk for patients having stage I/II/III disease was 52% greater (1.52-fold risk) while largest increase in risk for patients having stage III/IV disease was 67% greater (1.67-fold risk), both at CA125 ≥ 222U/ml. Patients with CA125 ≥ 122U/ml had significantly increased risk of +LNM, with maximum increase in risk of 98% (1.98-fold risk) at 222U/ml. Patients with CA125 ≥ 175U/ml had significantly increased risk of +LVSI, with maximum increase in risk of 39% (1.39-fold risk) at 222U/ml. This study shows that elevated CA125 levels correspond to increased stage, +LVSI, and +LNM in patients with EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.